Study on the antagonists for the orphan G protein-coupled receptor GPR55 by quantitative structure-activity relationship

Chemometrics and Intelligent Laboratory Systems

Volumn 131, Issue , 2014, Pages 51-60

  Deng, Fang Fang ^a   Xie, Mei Hong ^a   Li, Pei Zhen ^a   Tian, Yue Li ^a   Zhang, Xiao Yun ^a   Zhai, Hong Lin ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

CoMFA; CoMSIA; GPR55 antagonists; MLR; SMILES

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GPR55 ANTAGONIST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CORRELATION COEFFICIENT; DRUG DESIGN; DRUG DETERMINATION; MOLECULAR MODEL; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; SIMPLIFIED MOLECULAR INPUT LINE ENTRY SYSTEM; VALIDATION PROCESS;

EID: 84892852642     PISSN: 01697439     EISSN: 18733239     Source Type: Journal    
DOI: 10.1016/j.chemolab.2013.12.006     Document Type: Article

References (53)

1. Filmore D. It's a GPCR world. Mod. Drug Discovery 2004, 7:24-28.
2. Chung S., Funakoshi T., Civelli O. Orphan GPCR research. Br. J. Pharmacol. 2008, 153:S339-S346.
3. Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H., George S.R., O'Dowd B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res. 1999, 64:193-198.
4. Balenga N.A., Aflaki E., Kargl J., Platzer W., Schröder R., Blättermann S., Kostenis E., Brown A.J., Heinemann A., Waldhoer M. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011, 21:1452-1469.
5. Henstridge C.M., Balenga N.A., Kargl J., Andradas C., Brown A.J., Irving A., Sanchez C., Waldhoer M. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol. Endocrinol. 2011, 25:1835-1848.
6. Henstridge C.M., Balenga N.A., Schröder R., Kargl J.K., Platzer W., Martini L., Arthur S., Penman J., Whistler J.L., Kostenis E. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol. 2010, 160:604-614.
7. Obara Y., Ueno S., Yanagihata Y., Nakahata N. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells. PLoS One 2011, 6:e24284.
8. Anavi-Goffer S., Baillie G., Irving A.J., Gertsch J., Greig I.R., Pertwee R.G., Ross R.A. Modulation of l-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 2012, 287:91-104.
9. Ross R.A. l-α-Lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol. Sci. 2011, 32:265-269.
10. Henstridge C.M. Off-target cannabinoid effects mediated by GPR55. Pharmacology 2012, 89:179-187.
11. Sharir H., Abood M.E. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 2010, 126:301-313.
12. Moreno-Navarrete J.M., Catalán V., Whyte L., Díaz-Arteaga A., Vázquez-Martínez R., Rotellar F., Guzmán R., Gómez-Ambrosi J., Pulido M.R., Russell W.R. The l-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 2012, 61:281-291.
13. Funke M., Thimm D., Schiedel A.C., Muller C.E. 8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. J. Med. Chem. 2013, 56:5182-5197.
14. Rempel V., Volz N., Glaser F., Nieger M., Brase S., Muller C.E. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J. Med. Chem. 2013, 56:4798-4810.
15. Heynen-Genel S., Dahl R., Shi S., Milan L., Hariharan S., Sergienko E., Hedrick M., Dad S., Stonich D., Su Y. Screening for Selective Ligands for GPR55-Antagonists, Probe Reports from the NIH Molecular Libraries Program [Internet] 2010, 1-26. National Center for Biotechnology Information (US), Bethesda (MD).
16. Brown A.J., Daniels D.A., Kassim M., Brown S., Haslam C.P., Terrell V.R., Brown J., Nichols P.L., Staton P.C., Wise A. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J. Pharmacol. Exp. Ther. 2011, 337:236-246.
17. Clementi S., Wold S. How to choose the proper statistical method. Chemometrics Methods in Molecular Design 1995, 319-338. VCH, Weinheim. H. vande Waterbeemd (Ed.).
18. Wold S., Wold S. PLS for multivariate linear modeling. Chemometrics Methods in Molecular Design 1995, 195-218. VCH, Weinheim. H. vande Waterbeemd, H. vande Waterbeemd (Eds.).
19. AJAY A unified framework for using neural networks to build QSARs. J. Med. Chem. 1993, 36:3565-3571.
20. CORALSEA at:. http://www.insilico.eu/CORAL/.
21. Toropova A.P., Toropov A.A., Martyanov S.E., Benfenati E., Gini G., Leszczynska D., Leszczynski J. CORAL: QSAR modeling of toxicity of organic chemicals towards Daphnia magna. Chemometr. Intell. Lab. 2012, 110:177-181.
22. Cramer R.D., Bunce J.D., Patterson D.E., Frank I.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7:18-25.
23. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110:5959-5967.
24. Klebe G., Abraham U., Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37:4130-4146.
25. CODESSA software, 2.63 ed., University of Florida, SemiChem, Inc., 1994.
26. Benfenati E., Toropov A.A., Toropova A.P., Manganaro A., Diaza R.G. available at:, (CORALSEA Reference Manual). http://www.insilico.eu/coral/SOFTWARECORAL.html.
27. Toropov A.A., Toropova A.P., Rasulev B.F., Benfenati E., Gini G., Leszczynska D., Leszczynski J. CORAL: QSPR modeling of rate constants of reactions between organic aromatic pollutants and hydroxyl radical. J. Comput. Chem. 2012, 33:1902-1906.
28. http://www.daylight.com/.
29. Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 1988, 28:31-36.
30. Weininger D., Weininger A., Weininger J.L. SMILES. 2. Algorithm for generation of unique SMILES notation. J. Chem. Inf. Comput. Sci. 1989, 29:97-101.
31. Weininger D. SMILES. 3. DEPICT. Graphical depiction of chemical structures. J. Chem. Inf. Comput. Sci. 1990, 30:237-243.
32. Toropov A.A., Toropova A.P., Martyanov S.E., Benfenati E., Gini G., Leszczynska D., Leszczynski J. Comparison of SMILES and molecular graphs as the representation of the molecular structure for QSAR analysis for mutagenic potential of polyaromatic amines. Chemometr. Intell. Lab. 2011, 109:94-100.
33. Toropova A.P., Toropov A.A., Lombardo A., Roncaglioni A., Benfenati E., Gini G. A new bioconcentration factor model based on SMILES and indices of presence of atoms. Eur. J. Med. Chem. 2010, 45:4399-4402.
34. Zenkevich I., Moeder M., Koeller G., Schrader S. Using new structurally related additive schemes in the precalculation of gas chromatographic retention indices of polychlorinated hydroxybiphenyls on HP-5 stationary phase. J. Chromatogr. A 2004, 1025:227-236.
35. 60 solubility in organic solvents. Chem. Phys. Lett. 2007, 444:209-214.
36. Toropov A., Benfenati E. Additive SMILES-based optimal descriptors in QSAR modelling bee toxicity: using rare SMILES attributes to define the applicability domain. Bioorg. Med. Chem. 2008, 16:4801-4809.
37. 60 solubility in organic solvents. Chem. Phys. Lett. 2008, 457:332-336.
38. Sybyl software, 6.9 ed., Tripos Inc., 1999.
39. Clark M., Cramer R.D., Vanopdenbosch N. Validation of the general-purpose Tripos 5.2 force-field. J. Comput. Chem. 1989, 10:982-1012.
40. Gasteiger J., Marsili M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980, 36:3219-3228.
41. Sivan S.K., Manga V. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Mol. Model. 2010, 16:1169-1178.
42. Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978, 20:397-405.
43. Ståhle L., Wold S. Partial least squares analysis with cross-validation for the two-class problem: a Monte Carlo study. J. Chemom. 1987, 1:185-196.
44. Kearns M., Ron D. Algorithmic stability and sanity-check bounds for leave-one-out cross-validation. Neural Comput. 1999, 11:1427-1453.
45. Alexander G., Alexander T. Beware of Q2. J. Mol. Graph. Model. 2002, 20:269-276.
46. Roy P.P., Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb. Sci. 2008, 27:302-313.
47. Pratim Roy P., Paul S., Mitra I., Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009, 14:1660-1701.
48. Roy K., Pratim Roy P. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur. J. Med. Chem. 2009, 44:2913-2922.
49. Roy P.P., Roy K. QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. Chem. Biol. Drug Des. 2009, 73:442-455.
50. Ojha P.K., Mitra I., Das R.N., Roy K. Further exploring r2 m metrics for validation of QSPR models. Chemometr. Intell. Lab. 2011, 107:194-205.
51. Ojha P.K., Roy K. Comparative QSARs for antimalarial endochins: importance of descriptor-thinning and noise reduction prior to feature selection. Chemometr. Intell. Lab. 2011, 109:146-161.
52. Taemm K., Fara D.C., Katritzky A.R., Burk P., Karelson M. A quantitative structure-property relationship study of lithium cation basicities. J. Phys. Chem. 2004, 108:4812-4818.
53. Rohrbaugh R.H., Jurs P.C. Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships. Anal. Chim. Acta. 1987, 199:99-109.